Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05419427
Other study ID # 0774-19
Secondary ID CTRI/2021/09/036
Status Recruiting
Phase Phase 3
First received
Last updated
Start date November 11, 2021
Est. completion date November 24, 2024

Study information

Verified date October 2023
Source Lambda Therapeutic Research Ltd.
Contact Mr Prashant Modi
Phone 917940202375
Email prashantmodi@lambda-cro.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Denosumab of Intas is biosimilar denosumab candidate under development by Intas Pharmaceutical Limited (Biopharma Division). Denosumab of Intas is already approved by Indian drug licensing authority- Drug Controller General (India) for marketing in Indian population since 2018.As per regulatory requirement, a comparative clinical study to establish Pharmacokinetic, Pharmacodynamic and Immunogenicity equivalence is required to conclude therapeutic equivalence to obtain marketing authorization of a biosimilar investigational product. This is a multicenter, randomized, double-blind, active controlled study in approximately 552postmenopausal women with osteoporosis. An extension of the study is planned after completion of the initial 1 year of treatment. This extension is with the objective of submitting data on safety, and Immunogenicity, after switching of Prolia treatment arm to either Prolia or Intas denosumab for 6 months. This switching data is applicable only for FDA submission. Only patients who have undergone PK assessment will be eligible for the extension phase.


Recruitment information / eligibility

Status Recruiting
Enrollment 552
Est. completion date November 24, 2024
Est. primary completion date September 11, 2024
Accepts healthy volunteers No
Gender Female
Age group 55 Years to 90 Years
Eligibility Key Inclusion Criteria - Participant must sign an ICF to participate in the study indicating that she understands the purpose of, and procedures required for the study as described in this protocol and is willing to and will be able to adhere to requirement of the protocol. - Participant must be 55 to 90 years of age (both inclusive), at the time of signing the informed consent. - Participants whose absolute bone mineral density T-score is less than equal to -2.5 and greater than equal -4.0 at the lumbar spine as measured by DXA (dual-energy x-ray absorptiometry), confirmed by the independent central imaging team - At least two vertebrae in the L1-L4 region and at least one hip joint are evaluable by DXA, confirmed by the independent central imaging team. - Postmenopausal ambulatory female and not considered to be of child-bearing potential if: a. Women are considered post-menopausal and not of child-bearing potential if, i. They have had 12 months of natural (spontaneous) amenorrhea (no vaginal bleeding or spotting) with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) OR ii. Six months of spontaneous amenorrhea with serum FSH levels greater than 40 mIU per mL OR iii. Have had surgical bilateral oophorectomy (with or without hysterectomy) at least six months ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment if she is considered not of child-bearing potential Key Exclusion Criteria: - Documented medical history of clinically significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances - Documented medical history of known allergies, hypersensitivity, or intolerance to denosumab or its excipients (refer to the IB) - Documented medical history of metabolic or bone disease (except osteoporosis) that may interfere with the interpretation of the results, such as Pagets disease, osteomalacia, osteogenesis imperfecta, osteopetrosis, rheumatoid arthritis, ankylosing spondylitis or any other joint disease limiting mobility, Cushings disease, hyperprolactinemia, malabsorption syndrome - Contraindications to the use of denosumab or Vitamin D and Calcium as per IB/local prescribing information at screening and/or baseline - Documented medical history and/or current evidence of any of the following oral/dental conditions 1. Prior history or current evidence of osteomyelitis or osteonecrosis of the jaw. 2. Active dental or jaw condition which requires oral surgery. 3. Planned invasive dental procedure expected during study period. 4. Current evidence non-healed dental or oral surgery. 5. Current evidence of poor oral hygiene 6. Ill-fitting denture - Current hyper- or hypocalcemia, defined as albumin-adjusted serum calcium outside the normal range at screening. - Current, uncontrolled hyper- or hypoparathyroidism and history of hypoparathyroidism, per participant report or chart review. PTH outside the normal range (15-65 pg/mL) as assessed by central laboratory - Current, uncontrolled hyper- or hypothyroidism, defined as thyroid stimulating hormone outside of the normal range (TSH-0.465 to 4.68 mIU/L) at screening. - 25 (OH) Vitamin D lower than 20 ng/mL as assessed by the central laboratory at Screening. Vitamin D repletion will be permitted, and participants may be rescreened once. - History and /or presence of 1 severe fracture or 2 moderate vertebral fractures - Smokers or who have smoked within last 06 months prior to start of the study. - Administration of bisphosphonate as follows: - c. IV Bisphosphonate in the past 3 years d. Oral bisphosphonates treatment for osteoporosis i. More than 3 years of cumulative use ii. Any dose received within 6 months prior to randomization iii. More than 1 month of cumulative use between 6 and 12 months prior to randomization - Teriparatide or any PTH analogs treatment received within 12 months prior to randomization. - Systemic oral or transdermal estrogen, SERMs, or calcitonin treatment of more than 1 month of cumulative use within 6 months prior to randomization. - Androgen deprivation or hormonal ablation therapy of more than 1 month of cumulative use within 6 months prior to randomization. - Tibolone or cinacalcet treatment received within 3 months prior to randomization - Systemic glucocorticoids: Greater than equal to 5 mg prednisone equivalent per day for more than 10 days within 3 months prior to randomization.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Denosumab
Denosumab 60 MG/ML
Denosumab-Ref
Denosumab 60 MG/ML

Locations

Country Name City State
India S. R. Kalla Memorial Gastro & General Hospital Jaipur Rajasthan

Sponsors (2)

Lead Sponsor Collaborator
Lambda Therapeutic Research Ltd. Intas Pharmaceutical Limited (Biopharma Division)

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum measured concentration after first dose of denosumab and denosumab-ref., , Day 1 to Day 181
Primary Area under the concentration versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method between denosumab and denosumab-ref postmenopausal women with osteoporosis Day 1 to Day 181
Primary Area under the concentration versus time curve from time zero to infinity. Where AUC 0-8= AUC0-t + Ct2, Ct is the last measurable concentration and t2 is the terminal rate constant Day 1 to Day 181
Secondary Maximum percent reduction from baseline Emax percent reduction from baseline serum C-terminal telopeptide (CTX) after first dose of denosumab and denosumab-ref* Day 1 to Day 181
Secondary Area under the percent reduction from baseline versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method Day 1 to Day 181
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03931109 - Circulating miRNA in Primary Hyperparathyroidism
Not yet recruiting NCT03232476 - Effect of Mechanical Loading With PTH on Cortical Bone Phase 4
Completed NCT02884401 - Peri-implant Bone Changes in Post-menopausal Osteoporotic Women N/A
Completed NCT00073190 - Patient- and Physician-Based Osteoporosis Education Phase 1
Completed NCT00402441 - Risedronate in the Prevention of Osteoporosis in Postmenopausal Women Phase 4
Completed NCT03710889 - Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption Phase 3
Completed NCT00010712 - Effects of Black Cohosh on Menopausal Hot Flashes Phase 2
Recruiting NCT05058976 - Romosozumab Use to Build Skeletal Integrity Phase 4
Active, not recruiting NCT05405894 - Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
Recruiting NCT03337971 - Nutritional Supplement and Bone Health in Post-Menopausal Women N/A
Completed NCT03701113 - Milk Protein and Bone Health in Postmenopausal Women N/A
Completed NCT01381588 - The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women N/A
Completed NCT00383422 - Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis Phase 3
Completed NCT00549965 - Satisfaction and Compliance of Risedronate in PMO Phase 4
Completed NCT00035256 - Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis Phase 4
Completed NCT01386281 - Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
Completed NCT05266261 - Use of Ibandronate in Diabetic Patients N/A
Recruiting NCT04964388 - Effect of GLP-1 Receptor Agonists on Trabecular Bone Score Phase 2
Active, not recruiting NCT03623633 - Comparative Antiresorptive Efficacy Discontinuation of Denosumab Phase 4
Recruiting NCT05575167 - Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)